RGRXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (18 4月 2024 @ 02:13):

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration...

Stats
本日の出来高	15.00
平均出来高	99.00
時価総額	209 576
EPS	$-0.00380 ( 2023-03-30 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.140
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-03	Essetifin Spa	Buy	3 750 000	Common Stock Warrant (right to buy)
2023-07-03	Essetifin Spa	Buy	0	Convertible Promissory Note (right to buy)
2022-05-17	Goldstein Allan L	Buy	480 000	Stock Option (Right to Buy)
2022-05-17	Goldstein Allan L	Buy	480 000	Stock Option (Right to Buy)
2022-05-17	Bove Mauro	Buy	240 000	Stock Option (right to buy)

INSIDER POWER
100.00
Last 98 transactions
Buy: 35 451 124 \| Sell: 5 867 027

RegeneRx 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

RegeneRx 財務諸表

Annual	2022
収益:	$76 761.00
総利益:	$76 761.00 (100.00 %)
EPS:	$-0.0120

FY	2022
収益:	$76 761.00
総利益:	$76 761.00 (100.00 %)
EPS:	$-0.0120

FY	2021
収益:	$76 761.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.0120

FY	2020
収益:	$76 761.00
総利益:	$76 761.00 (100.00 %)
EPS:	$-0.0100

Financial Reports:

No articles found.

RegeneRx

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.